Background/Aims: Galectin-9 is a soluble immune modulator with versatile functions, including a role as an immune checkpoint molecule. Therefore, the amount of galectin-9 in the blood may reflect an individual's immunological balance. Many studies have conducted galectin-9 measurements; however, the reported galectin-9 concentration in the blood varies greatly, even within healthy controls. This study investigates the variation between the reported and actual concentrations of galectin-9. Methods: A GalPharma ELISA and an R&D Systems ELISA kit were directly compared using the same set of plasma and a series of recombinant galectins, including degraded galectin-9. Furthermore, galectin-9 in plasma was concentrated using anti-galectin-9 antibody-conjugated beads, and subjected to western blotting to estimate the quantity and integrity of galectin-9 and assess the consistency of ELISA measurements. Results: The R&D Systems' ELISA indicated a 50-fold higher median concentration of plasma galectin-9 than that indicated by the GalPharma ELISA. This variation is due to aberrantly enhanced reactivity of the R&D Systems' ELISA to degraded galectin-9 present in small quantities in the plasma. The GalPharma ELISA could detect only intact galectin-9 and its results correlated well with the plasma galectin-9 level obtained by western blotting. Conclusion: ELISA kits from R&D Systems reacts aberrantly higher against degraded galectin-9 than the intact galectin-9. Therefore, the existence of a small amount of degraded galectin-9 in a test sample hinders the quantification. As galectin-9 is a fragile protein, this is a serious concern when using this kit. Based on quantifications from the GalPharma ELISA, the median (25 th -75 th percentiles) galectin-9 concentration in healthy subjects in the current study cohort was calculated as 110 pg/mL (67 -154 pg/mL).
Introduction
Galectin-9 (Gal-9) is a β-galactoside-binding animal lectin of the galectin family that is expressed ubiquitously in tissues and cells, with particular abundance in the immune and epithelial cells of gastrointestinal tracts. Gal-9 suppresses T helper type 1 (Th1) and Th17 cells and activates regulatory T (Treg) cells both in vitro and in vivo, which explains the antiinflammatory effects of Gal-9 administration in autoimmune and allergic animal models [1] . Recently, Gal-9 was annotated as an immune checkpoint molecule, together with its receptor T-cell immunoglobulin and mucin domain 3 (Tim-3) [2] . Recent research has focused on the strategy to neutralize this lectin in an attempt to reactivate immune cells to fight against cancers and/or infections. Contrary to this goal, Gal-9 demonstrates anti-cancer effects in several tumor-bearing mouse models by either inducing apoptosis of cancer cells or activating immune cells such as dendritic cells, NK cells, and cytotoxic T cells [3] [4] [5] [6] . Several retrospective studies clarified the positive correlations between Gal-9 expression in cancer tissues and improved patient prognosis in various cancer types [7] . These observations are inconsistent with the well documented immune suppressive function of Gal-9 and have revealed that Gal-9 biology is complex and poorly understood.
Because Gal-9 is a multi-functional immune modulator, and the only known soluble immune checkpoint molecule, its concentration in the blood may reflect an individual's immune balance and could be a useful clinical biomarker. Using a GalPharma (GalP) ELISA, we have reported that the concentration of Gal-9 in the blood fluctuates rapidly, reflecting the pathological conditions of patients with various diseases [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Similar disease-related fluctuations have been reported using both independently developed and commercially produced ELISAs [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . When the reported Gal-9 concentrations were compared, a large divergence was observed in the results, even within healthy control groups, with values ranging from 0 to 26, 560 pg/mL. It is unlikely that these variations are the result of sample set differences such as participant race, use of plasma vs. serum, collection methods, or statistical analysis methods. This study examined the factors that might influence the variations observed in Gal-9 values reported in the literature and aimed to provide an accurate measurement of the concentration of functional Gal-9 in the blood.
Materials and Methods

Ethics Statement
The study protocol was approved by the Institutional Review Boards at the University of Colorado Health Sciences Center, Denver and the Oregon Health Sciences University, Portland. Both written and oral consent was obtained from participants before samples were collected. Degradation of Gal-9 by elastase Highly purified wild-type Gal-9 S-type variant (66 µg/mL) was incubated with 0.96 µg/mL of elastase (Sigma-Aldrich, St. Louis, MO, USA) in a buffer containing 100 mM Tris-HCl (pH8.0) and 1 mM CaCl 2 at 37°C. At the indicated time point, 5 µL of the reaction was transferred into a micro tube containing 15 µL of Complete Protease Inhibitor Cocktail (Roche Diagnostics, Rotkreuz, Zug, Switzerland), then subjected to SDS-PAGE and ELISA.
Detection of plasma Gal-9 by western blotting Anti-Gal-9(N) polyclonal antibody was produced by immunizing rabbits (Japanese White) with recombinant Gal-9(N) and purified from the rabbit serum with an affinity column prepared by binding the antigen to a HiTrap NHS-activated column (GE Healthcare). After purity and titer assurance, the antibody was then conjugated to a fresh HiTrap NHS-activated column. The resulting antibody-bound resin was removed and suspended in Binding buffer (PBS containing 2 mM EDTA, 0.1% sodium azide, and 2 x Complete Protease Inhibitor Cocktail). Plasma (150 µL) was diluted with Binding buffer (130 µL) then mixed with a 25% slurry of anti-Gal-9(N) antibody-conjugated resin in a spin column (20 µL) (MoBiTec, Lotzestrasse, Göttingen, Germany). When indicated, recombinant Gal-9(0) and Gal-9(N) was added at 225 pg each. The reaction mixture was incubated for 4 h, while gently mixed on a rotator, at 4°C. The unbound fraction was removed by washing the column twice with PBS containing 0.05% tween-20. Gal-9 left in the column was released by the addition of 14 µL of SDS-PAGE sample buffer containing 4% SDS, 8 M urea and 10% 2-mercaptoethanol. The samples were subjected to SDS-PAGE, transferred to an Immobilon PVDF membrane (Merck, Frankfurter Strasse, Darmstadt, Germany), and assessed using the antibodies antihuman Gal-9 mouse monoclonal antibody (9S2-1, GalPharma, Takamatsu, Kagawa, Japan) with anti-mouse IgG horse-radish peroxidase conjugate (BioLegend, San Diego, CA, USA) for full-length Gal-9, and anti-Gal-9(N) rabbit polyclonal antibody with anti-rabbit IgG horse-radish peroxidase conjugate (GE Healthcare) for degraded Gal-9. The signal was visualized by ECL prime (GE Healthcare) and a lumino-image analyzer LAS4010 (GE Healthcare). The digital data was processed using ImageJ (NIH Image, Bethesda, MD, USA) and the amount of Gal-9 was quantified using a standard constructed with recombinant Gal-9(0) and Gal-9(N).
Presentation of data
All the experiments were reproduced at least twice, and representative data was presented. For statistical analysis, the Mann-Whitney U-test and Spearman's rank correlation coefficient were used to assess the difference and correlation between a set of non-parametric data using Prism 5 (GraphPad software, La Jolla, CA, USA).
Results
Plasma Gal-9 quantities differ significantly based on the ELISA products employed From publications assessing blood Gal-9 levels by ELISA, we selected reports that quantified Gal-9 concentration in a healthy control (HC) and summarized the data in Table  1 . The Gal-9 concentration, either in plasma or serum, is widely varied even within the HC groups, and ranges from 0 to 26, 560 pg/mL. These large variations, however, can mostly be attributed to the ELISA kit employed, as much higher values were obtained with the R&D Systems (RDS) as compared to the other 5 manufacturers' products ( Fig. 1) . The median Gal-9 levels in HC were 5, 061 pg/mL and 89 pg/mL from the RDS and the combined data from the other ELISAs respectively, which is a significant difference (p = 0.0003). On the other hand, the variation between the other 5 ELISA products was not significantly different. Specifically, the Gal-9 levels determined with the GalP ELISA was compared with those obtained with the other 4 ELISAs and did not show a significant difference, and the other combinations were invalid because of few examples.
Using plasma from patients with acute liver failure (ALF) and HC, we directly compared the RDS and GalP ELISAs (Table 2 and 3 and Fig. 2A and 2B ). ALF demonstrated significantly higher Gal-9 levels compared with HC in both ELISAs (p < 0.0001), hence the ALF-related increment of plasma Gal-9 that we published already using the GalP ELISA was reproduced Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Table 1 . Reported Gal-9 concentration in the blood from healthy control (HC) and patients represented by Mean, Median, or Geometric mean. ELISA makers are abbreviated as follows. GalP = GalPharma, BGB = Blue Gene Biotech, RDS = R&D Systems using the RDS ELISA. However, the actual Gal-9 values were different between the two kits, with the median values (pg/mL) of ALF vs HC as 23, 049 and 5, 355 respectively when determined with RDS ELISA and 426 and 110 respectively when determined with GalP ELISA. RDS ELISA indicated Gal-9 levels 54-fold higher in ALF and 49-fold higher in HC when compared to those obtained with GalP, which confirmed the hypothesis that RDS ELISA would obtain higher Gal-9 values. Fig. 2C examined the correlation of both measurements. They are correlated, though the correlation is not very strong (ALF: r = 0.5632, n = 23, p = 0.0051; HC: r = 0.5445, n = 17, p = 0.0238).
Characterization analysis of RDS and GalP ELISAs
Quantification by ELISA is affected by the purity and integrity of the Gal-9 standard used to generate the calibration curve. When degradation occurs in standard Gal-9, it may shift the calibration curve and result in an overestimation of the quantity of Gal-9 in the test samples. As shown in Fig. 3A , Gal-9 consists of carbohydrate-recognition domains at the N-terminus and C-terminus with a linker peptide in between. Since Gal-9 is a fragile protein, and degradation starts at the linker peptide, the prepared Gal-9 samples may contain the Fig. 1 . Blood Gal-9 concentration determined by RDS ELISA compared to that determined by 5 other products. Gal-9 concentration (pg/mL) in serum or plasma from Healthy Controls (HC), expressed either as the median or mean, extracted from 21 publications and divided into two groups based on the manufacturer; R&D Systems (n = 7) or the other 5 manufacturers (n = 14). The other manufacturers include Uscn, Blue Gene Biotech, AMS, Kamiya, and GalP. P -value was calculated using the two tailed Mann-Whitney U-test.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry truncated forms, Gal-9(N) and Gal-9(C), as well as other degradation products. We suspected that such a degradation might have occurred in the RDS ELISA, which may explain the higher Gal-9 levels observed when compared with the values obtained by GalP ELISA. The GalP ELISA, on the other hand, uses a linker-less artificial form of Gal-9 (Gal-9(0)) that remains highly stable in long-term storage without any changes to protein integrity [32] and allows for reliable quantification. Standard preparations of RDS ELISA and GalP ELISA were compared ( Fig. 3B and 3C ). Contrary to our hypothesis, the calibration curves generated with both preparations overlapped in both ELISA systems (r = 1.000, n = 8, p < 0.0001; for both comparisons). This excluded the possibility of poor Gal-9 standard in the RDS ELISA. Since both standard preparations were found to produce identical ELISA measurements, Gal-9(0) was used as a common standard, unless otherwise stated, in the subsequent experiments.
The galectin family has 10 members in humans. Even though the amino acid homology among galectins is only 20-35%, we found that polyclonal antibodies against Gal-9 often cross-reacted with other galectins. As several galectins were detected in the serum [26, 27, 36, 37] , low specificity could Comparison between RDS and GalP ELISAs. Gal-9 concentration measured in plasma from acute liver failure patients (ALF, n = 23) and HC (n = 17) using ELISAs from RDS (A) and GalP (B). P -value was calculated using the two tailed Mann-Whitney U-test. (C) Correlation between RDS ELISA and GalP ELISA measurements were assessed in ALF and HC independently using the Spearman's coefficient (ALF: r = 0.5632, n = 23, p = 0.0051; HC: r = 0.5445, n = 17, p = 0.0238). 
To further understand variations between the ELISAs, we generated concentrationdependent curves using the proteins recognized by each ELISA (Fig. 3F and 3G) . The curves for Gal-9 (MW: 34, 559) and its linker-less form Gal-9(0) (MW: 33, 014) overlapped in both ELISAs. Examination of Gal-9(N) using the RDS ELISA yielded higher reactivity than that observed for Gal-9 or Gal-9(0), with the curve shifted 6-fold lower than that produced by Gal-9 and Gal-9(0). Since the molecular weight of Gal-9(N), which is 18, 193, is about half that of the full-length protein, the molar concentration is about 2-fold higher than full-length Gal-9. This could not account for all of the 6-fold difference. We hypothesized that the RDS ELISA might have higher reactivity against Gal-9(N) than against the intact full-length Gal-9. We considered two possibilities to explain the variation in observed Gal-9 concentrations measured by two ELISA systems. 1) The presence of a large amount of degraded Gal-9 in the blood. 2) Higher reactivity of the RDS ELISA against degraded Gal-9.
Degradation of Gal-9 hinders quantification by RDS ELISA
Because Gal-9 is known to be digested by elastase in vivo [38] , highly purified Gal-9 was incubated with elastase, sampled at the indicated time points by addition into a protease inhibitor cocktail, and then examined by SDS-PAGE with silver staining and ELISA ( Fig.  4A and 4B) . The bands at approximately 33 kDa, corresponding to intact Gal-9, gradually decreased over time and almost disappeared by 4 h. Inversely, several bands slightly above 15 kDa, corresponding to the degradation products at the linker peptide, increased with time. Even though there are many elastase recognition sites in the protein, digestion seems to occur mainly at the linker peptide at the given incubation time. Measurement with the GalP ELISA correlated well with the gradual degradation of intact Gal-9 observed in the SDS-PAGE gel. Measurement with RDS ELISA, however, indicated an apparent increase in the amount of Gal-9 as the degradation progressed, and reached about 4-fold higher than the original concentration by the end of the incubation. As we hypothesized based on the data in Fig. 3F , the RDS ELISA demonstrated higher reactivity against degraded Gal-9, which distorted the Gal-9 measurement for the test samples.
Detection of plasma Gal-9 by western blotting
If a large quantity of degradation products exist in the blood, they might be detected by western blotting. However, the high concentration of plasma proteins allows only 0.25 µL/ well for SDS-PAGE. This indicates, even with the plasma containing the highest concentration of Gal-9 at 64, 392 pg/mL in an ALF by RDS ELISA assessment (1, 929 pg/mL by GalP ELISA), that western blotting can process only about 16 pg/well of Gal-9. This quantity is marginal compared to the detection limit with pure Gal-9 and our most sensitive detection methods, and it is not detectable when the degradation products do not form a single band. Therefore, we purified Gal-9 from the plasma using a spin column containing anti-Gal-9(N) antibody-conjugated beads (Fig. 5A) . As RDS does not provide the antibodies from their ELISA separately, we prepared a polyclonal antibody against Gal-9(N) for the purpose. Plasma test samples were collected based on two criteria, sufficient volume to be supplied for purification and a previously established deviation from the correlation between RDS and GalP ELISA measurements (Fig. 5B) . Samples A to E are from HC plasma and produced a variable Gal-9 concentration when assessed with a GalP ELISA, but approximately the same concentrations were obtained with the RDS ELISA. Sample A and B derive from the same plasma, but Sample A was supplemented with recombinant Gal-9(0) and Gal-9(N) to act as the positive control for this purification strategy. Samples F through H were from ALF plasma; these samples showed variable Gal-9 concentrations as determined by GalP ELISA, but similar concentrations when subjected to RDS ELISA.
Selected plasma (150 µL) was loaded into the column, incubated, and then unbound materials were washed out. Gal-9 in the unbound fraction was measured by both ELISA systems to estimate the amount of Gal-9 left in the column. Finally, Gal-9 was released with small amount of SDS-PAGE sample buffer, then used for SDS-PAGE and subsequent western blotting (Fig. 5C ). Signals were observed, in some samples, at the molecular weights corresponding to Gal-9, Gal-9(0), and Gal-9(N), as well as positions lower than Gal-9(N), indicated by Gal-9(deg), with approximate sizes of 12 -16 kDa. These signals were used to determine the quantity of Gal-9 through comparison to a standard constructed with Gal-9(0) and Gal-9(N) ( Table 4 ). There are three isoforms of wild-type Gal-9 differing in the length of the linker peptide and referred to as Large (L), Medium (M), and Small (S) isoforms. The M-isoform is dominant in terms of expression [39, 40] . In this western blot, we quantified only the M-isoform, because position for the M-isoforms displayed the only clear signal. Fig.  5D and Table 5 summarize the yield in the purification steps where Start and Bound were quantified by RDS ELISA. Eluate represents the total amount of Gal-9, Gal-9(0), Gal-9(N), and Gal-9(deg) determined by western blotting. As mentioned, Sample A was prepared by adding recombinant Gal-9(0) and Gal-9(N) to Sample B, but the high basal level of Sample B, determined by RDS measurement, made the increase caused by the recombinant proteins appear minor (Fig. 5D ). More than 96% of Gal-9 signals were bound to the column in all cases. This indicates that only 10% of Gal-9 from the column is enough to produce substantial signals from any samples when western blotting, if the plasma contains a large amount of degraded Gal-9. However, such degradation products were observed only in samples F, G, and H, at far lower amounts than estimated, even though the same antibody was used in the spin column and for western blotting. As this western blotting is for proteins of 11 kDa or more, it is possible that the majority of the degradation products are smaller. However, when HC plasma was filtered with an ultrafiltration devise with the molecular weight cut-off of 10 kDa, no signal was detected in the flow-through fraction by RDS ELISA (Data not shown), which eliminated the possibility of smaller degradation products. Fig. 5E and Table 6 summarize the purification steps where the GalP ELISA was used for Start and Bound measurement and Eluate is the amount of Gal-9 plus Gal-9(0) that this ELISA can detect. In contrast to the nearly perfect binding to the column determined by the RDS ELISA, the binding determined by GalP was variable with a range of 55% to 100% depending on the samples. Elution efficiency in samples A, E, F, and G was 25~50%. These levels of efficiency are within the expected range for purification. We detected intact Gal-9 in the plasma by western blotting in samples A, E, F, and G, which includes both HC and ALF samples, but these were identified as having high Gal-9 levels by GalP ELISA (Fig. 5B) . Additionally, Sample H is from ALF plasma but has low Gal-9 expression, as determined by GalP ELISA. Hence, western blotting did not detect intact Gal-9 in this sample. The GalP ELISA measurements demonstrated a very strong correlation with the existence of intact Gal-9 in the plasma samples (Fig. 5F , r = 0.9132, n = 8, p = 0.0022). 
Discussion
Numerous studies have been published on the correlation between Gal-9 concentration in the blood and various pathological conditions. These studies show large differences in the Gal-9 concentrations, even in the healthy control groups, and those differences could be attributed to the choice of ELISA products. By a direct comparison, with the same plasma samples, we confirmed that the RDS ELISA quantifies an approximately 50-fold higher median Gal-9 concentration than that determined with the GalP ELISA. We proposed two hypotheses to explain the variation between these measurements. 1) The RDS ELISA has higher reactivity against degraded Gal-9. 2) There is significantly more degraded Gal-9 in the plasma. The 1 st hypothesis was confirmed through Gal-9 digestion with elastase, Table 4 . Quantity of Gal-9 species in eluate determined by western blotting. The quantity is expressed in picograms. Gal-9(deg) represents bands smaller than Gal-9(N), with an approximate size of 12 -16 kDa Table 5 . Quantity of Gal-9 in each fraction determined by RDS ELISA. Both A and B are based on HC-17 plasma, but only A was supplemented with recombinant Gal-9(0) and Gal-9(N) (225 pg each) to act as positive control. The starting material for Sample A contains 1274 pg of Gal-9 (824 pg out of HC-17 + 225 pg of Gal-9(0) + 225 pg of Gal-9(N)). The amount of Bound Gal-9 was calculated by subtracting the Unbound Gal-9 measured by ELISA from the Start Table 6 . Quantity of Gal-9 in each fraction determined by GalP ELISA. The same fractions in Table 5 . were measured. Since GalP ELISA does not react with truncated Gal-9, the starting material for Sample A contains 235 pg of Gal-9 (10 pg out of HC-17 + 225 pg of Gal-9(0)) that is measurable with this ELISA Cellular Physiology and Biochemistry
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where complete digestion at the linker peptide falsely increased the quantification 4-fold. To examine the 2 nd hypothesis, we concentrated Gal-9 in the plasma using an anti-Gal-9(N) antibody column and tried detecting degraded Gal-9 by western blotting. There was a small quantity of degraded Gal-9 with a size smaller than the products of elastase digestion. We conclude that these small quantities of degradation products in the blood are the causative of the approximately 50-fold higher estimation of Gal-9 in blood determined by RDS ELISA. Blood born degraded Gal-9 likely has a higher reactivity than the products of elastase digestion when measured by RDS ELISA.
The aberrant results from RDS ELISA may be the product of antibodies that bind strongly against degraded or denatured Gal-9. Antibodies of this kind are sometimes generated when a peptide antigen is used in place of whole protein for immunization. Degradation may expose epitopes against these antibodies or destroy the tertiary structure that the epitopes are incorporated into when Gal-9 is intact enough. This degradation allows these antibodies to bind, and results in higher signals that are falsely translated into a higher estimated Gal-9 concentration. It is likely that human specimens of any kinds will contain degraded Gal-9, which would distort the quantification by RDS ELISA, hence the kit has little value for quantification of Gal-9 in test samples. On the contrary, the GalP ELISA measurements correlated well with the amount of intact Gal-9 in the plasma (Fig. 5F ), which confirmed the reliability of the system. Using the GalP ELISA we measured 23 ALF (Table 2 ) and 17 HC (Table 3 ) samples and obtained medians (25 th -75 th percentiles) of 426 pg/ml (285 -799 pg/ mL) and 110 pg/mL (67 -154 pg/mL) respectively. This concentration is close to the expected Gal-9 concentration in the current cohort. The generalization of normal Gal-9 values beyond the current study will require the accumulation of more data, as Gal-9 assessment vary significantly depending on the country [Unpublished data]. Differences such as race, dietary habits, and unrecognized infections might change the Gal-9 expression in the blood, which should be examined in the future.
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